The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

MLA

Sho Sato, et al. “The New Prognostic Score for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab: A Multi‐institutional Cohort Study.” Annals of Gastroenterological Surgery, vol. 5, no. 6, Nov. 2021, pp. 794–803. EBSCOhost, https://doi.org/10.1002/ags3.12489.

APA

Sho Sato, Yoko Oshima, Yu Matsumoto, Yasuyuki Seto, Hiroharu Yamashita, Koichi Hayano, Masayuki Kano, Hidetaka Andrew Ono, Norio Mitsumori, Muneharu Fujisaki, Chikara Kunisaki, Hirotoshi Akiyama, Itaru Endo, Yasushi Ichikawa, Hidejiro Urakami, Hirokazu Kubo, Sakae Nagaoka, & Hideaki Shimada. (2021). The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study. Annals of Gastroenterological Surgery, 5(6), 794–803. https://doi.org/10.1002/ags3.12489

Chicago

Sho Sato, Yoko Oshima, Yu Matsumoto, Yasuyuki Seto, Hiroharu Yamashita, Koichi Hayano, Masayuki Kano, et al. 2021. “The New Prognostic Score for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab: A Multi‐institutional Cohort Study.” Annals of Gastroenterological Surgery 5 (6): 794–803. doi:10.1002/ags3.12489.